01—Abstract
Summary
Summary of the 8-K filed January 12, 2026. Cited figures are marked; the original filing is the authoritative source.
Regeneron (REGN) filed this 8-K on January 12, 2026, furnishing a J.P.
Morgan Healthcare Conference presentation by CEO Leonard Schleifer and CSO George Yancopoulos. The filing is primarily a corporate update with preliminary, unaudited Q4 and full-year 2025 information that remains subject to closing procedures. Two discrete items were disclosed: an acquired in-process R&D (IPR&D) charge of approximately $19 milliona pre-tax in Q4 2025, which reduces both GAAP and non-GAAP diluted EPS by about $0.14, and an approximately $60 million matching contribution to the Good Days Retinal Vascular and Neovascular Disease Fund, recorded in SG&A.
The presentation shows strong commercial momentum. Dupixent global net sales were $736Mb in Q4 2025 per the slide, and EYLEA HD physician demand grew 10% quarter over quarter. Management noted that Q4 EYLEA HD and EYLEA U.S. net sales were each favorably impacted by roughly $30 million from higher wholesaler inventory, so underlying demand is somewhat lower than reported.
Management also reported capital returns of about $3.8 billionc in 2025 (roughly $3.4 billion in buybacks and $0.4 billion in dividends), with a quarterly dividend of $0.88 per share initiated in 2025 and about $1.5 billion remaining under the repurchase authorization. Projected 2026 non-GAAP R&D spend is above $7 billion, and GAAP R&D is estimated at about $6.5 billion. For investors, the filing's near-term catalysts are concentrated in 1H 2026: pivotal fianlimab plus cemiplimab data in first-line metastatic melanoma, a DB-OTO FDA decision, an EYLEA HD pre-filled syringe decision in 2Q 2026, and several Factor XI and obesity Phase 3 starts.
Formal 2026 financial guidance was deferred to the Q4 2025 earnings release. The filing also flags pending DOJ-related litigation and EYLEA patent litigation as risk factors.
02—Key points
Key Highlights
- Q4 2025 acquired IPR&D charge of approximately $19 million pre-tax, reducing GAAP and non-GAAP diluted EPS by about $0.14
- Approximately $60 million Q4 2025 matching contribution to the Good Days retinal disease fund, recorded in SG&A, under a program capped at $200 million
- Dupixent global net sales of $736M in Q4 2025 per the presentation, with Sanofi recording the sales; EYLEA HD and EYLEA U.S. Q4 results each benefited from roughly $30 million of wholesaler inventory build
- 2025 capital returns of about $3.8 billion ($3.4 billion buybacks, $0.4 billion dividends); quarterly dividend of $0.88 per share; about $1.5 billion remaining under the repurchase program
- 2026 non-GAAP R&D expected above $7 billion (GAAP about $6.5 billion); about $6 billion committed to U.S. manufacturing and R&D infrastructure over coming years
- Key 1H 2026 catalysts include fianlimab plus cemiplimab Phase 3 melanoma data, DB-OTO FDA decision, and EYLEA HD pre-filled syringe FDA decision in 2Q 2026
- Preliminary, unaudited results remain subject to closing procedures, and formal 2026 guidance is deferred to the Q4 2025 earnings release
03—Questions
Frequently Asked Questions
How much will the Q4 2025 IPR&D charge affect Regeneron's earnings?
The company expects an acquired IPR&D charge of about $19 million pre-tax, which lowers both GAAP and non-GAAP diluted EPS by approximately $0.14 for Q4 2025. Regeneron does not forecast such charges because their timing and size are uncertain.
Why does the Good Days donation matter for Q4 results?
Regeneron committed to a one-to-one matching program of up to $200 million for donations to the Good Days retinal disease fund through 2025. The Fund received about $60 million in Q4 2025 donations, so Regeneron recorded a roughly $60 million matching charge in SG&A, which weighs on reported SG&A expense.
Were EYLEA and EYLEA HD sales inflated by inventory timing in Q4 2025?
Yes. Management stated that Q4 2025 EYLEA HD and EYLEA U.S. net product sales were each favorably impacted by about $30 million from higher wholesaler inventory at year-end versus Q3. Underlying demand growth was smaller than the reported sales figures suggest, although EYLEA HD physician demand grew 10% quarter over quarter.
What are the most important near-term catalysts for Regeneron?
Key 1H 2026 events include Phase 3 data for fianlimab plus cemiplimab in first-line metastatic melanoma, an FDA decision on DB-OTO for genetic hearing loss, and an FDA decision on the EYLEA HD pre-filled syringe expected in 2Q 2026. Additional Factor XI and obesity Phase 3 programs are also slated to begin in 2026.
How is Regeneron returning capital and investing in R&D?
Regeneron returned about $3.8 billion to shareholders in 2025, mostly through buybacks, and initiated a $0.88 quarterly dividend. It expects 2026 non-GAAP R&D spend above $7 billion and has committed about $6 billion over coming years to U.S. manufacturing and R&D infrastructure. The company also continues to use selective business development, including the GLP-1/GIP in-licensing and the Alnylam and Tessera collaborations.
04—Continue